← All indications
Systemic Vasculitis
A heterogeneous group of diseases characterized by inflammation and necrosis of the blood vessel walls.
Subtype terms (3)
More specific conditions that are subtypes of Systemic Vasculitis in the MeSH hierarchy.
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
48 drugs (29 approved, 19 experimental)
- Polyarteritis Nodosa
17 drugs (16 approved, 1 experimental)
- Rheumatoid Vasculitis
Drugs by status
Approved for this indication (2)
Phase 4 trials (4)
Phase 3 trials (1)
Phase 2 trials (2)
Organizations
Organization Involved with Phase 4 Indications (13)
Organization Involved with Phase 3 Indications (21)
- Bristol-Myers Squibb
- AstraZeneca
- GlaxoSmithKline
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of Pennsylvania
- Johns Hopkins University
- University of Michigan
- University of Rochester
- University of South Florida
- University of Birmingham
- Mayo Clinic
- University of Colorado, Denver
- University of Freiburg
- Institut mutualiste, Paris, France
- Immune Tolerance Network
- National Center for Advancing Translational Science (NCATS)
- Assistance Publique - Hôpitaux de Paris
- Versus Arthritis
Organization Involved with Phase 2 Indications (4)
Organization Involved with Other Experimental Indications (1)